We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises
Relationship to Other Peptides PEG-MGF and IGF-1 LR3 are part of a broader growth and regeneration network
Another limitation is that using siblings as a comparison group, the age difference between the two groups can introduce some bias, and this must be taken into account in interpreting the results
New York Times Copyright 2024 HealthDay
Eur J Med Chem 46:58855893 Shiferaw WS, Akalu TY, Aynalem YA (2020) Prevalence of erectile dysfunction in patients with diabetes mellitus and its association with body mass index and glycated hemoglobin in Africa: a systematic review and meta-analysis
The breadth of these effects is the point: the receptor does not appear to act through a single disease-specific mechanism but through a general increase in neuronal resilience
